NCT07508488Phase 2Recruiting
Deucravacitinib in the Treatment of Cicatricial Alopecias
In the register
The register attaches this trial to Deucravacitinib (Bristol Myers Squibb), currently at “Phase 2” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Recruiting
- Declared phase
- Phase 2
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Participants (registry)
- 20
- Start
- May 2026
- Primary completion
- June 2028 (planned)
- Study completion
- September 2028 (planned)
- Last registry update
- July 2026
- Countries
- United States
Conditions studied: Central Centrifugal Cicatricial Alopecia, Frontal Fibrosing Alopecia
Interventions: Deucravacitinib
Other trials of Deucravacitinib
A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.